Affimed

Affimed NV engages in the discovery and development of cancer immunotherapies. It is a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer by actualizing the untapped potential of the innate immune system. The company’s proprietary ROCK platform enables a tumor-targeted approach to recognize and kill a range of hematologic and solid tumors, enabling a broad pipeline of wholly-owned and partnered single agent and combination therapy programs. The ROCK platform predictably generates customized innate cell engager molecules, which use patient's immune cells to destroy tumor cells. The company was founded in 2000 and is headquartered in Heidelberg, Germany.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Affimed reports Q1 loss, positive clinical data in cancer treatments

Affimed's Q1 2024 performance showed a net loss but highlighted positive clinical data and progress in cancer treatments.
Despite enrollment delays in the LuminICE trial, Affimed's programs leveraging the innate immune system demonstrate consistency and success.
Addressing financial challenges, patient enrollment issues, and leveraging opportunities in future study phases and partnerships are key for Affimed's growth.

Affimed reports Q3 performance, highlights clinical milestones, and eyes partnerships

Affimed's Q3 2024 performance reflects a net loss of EUR 15.1 million but maintains a solid cash position of EUR 24.1 million.
Management's focus on clinical milestones, safety profiles, and upcoming updates at ASH 2024 demonstrates a commitment to innovation.
Challenges lie in meeting data expectations, navigating partnerships, and balancing financial stability with growth aspirations.
Opportunities abound in showcasing progress at ASH 2024, exploring partnerships, and advancing clinical programs for future success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Affimed NV is a clinical-stage immuno-oncology company, which engages in the discovery and development of cancer immunotherapies. The company’s proprietary ROCK platform enables a tumor-targeted approach to recognize and kill a range of hematologic and solid tumors, enabling a broad pipeline of wholly-owned and partnered single agent and combination therapy programs. It operates through the Germany and USA geographical segments. The company was founded in 2000 and is headquartered in Mannheim, Germany.

Heidelberg, Germany, December 17, 2019 – Affimed N.V. (Nasdaq: AFMD), a clinical stage biopharmaceutical company committed to giving patients back their innate ability to fight cancer, today announced that it has been selected for addition to the NASDAQ Biotechnology Index (Nasdaq: NBI). The addition to the NASDAQ Biotechnology Index will become effective prior to market open on Monday, December 23, 2019.

Affimed Announces Addition to NASDAQ Biotechnology Index

Affimed N.V. (AFMD) CEO Adi Hoess on Q3 2019 Results - Earnings Call Transcript

Affimed N.V. (AFMD) delivered earnings and revenue surprises of -35.71% and -65.47%, respectively, for the quarter ended September 2019.

Affimed N.V. (AFMD) Reports Q3 Loss, Misses Revenue Estimates

Affimed Reports Third Quarter 2019 Financial Results and Recent Operational Progress

Heidelberg, Germany, November 14, 2019 – Affimed N.V. (Nasdaq: AFMD), a clinical stage biopharmaceutical company committed to giving patients back their innate ability to fight cancer, today announced that Dr. Adi Hoess, CEO, will present at the Jefferies 2019 London Healthcare Conference on Wednesday, November 20, 2019 at 3:20 pm GMT / 10:20 am ET in London.

Affimed to Present at the Jefferies 2019 London Healthcare Conference

Affimed Announces Closing of Public Offering of Common Shares and Exercise of Underwriters’ Option to Purchase Additional Shares

Heidelberg, Germany, November 8, 2019 – Affimed N.V. (“Affimed” or the “Company”) (Nasdaq: AFMD), a clinical stage biopharmaceutical company committed to giving patients back their innate ability to fight cancer, today announced the pricing of its previously announced public offering of 12,000,000 of its common shares at a public offering price of $2.50 per common share. In addition, Affimed has granted the underwriters a 30-day option to purchase up to an additional 1,800,000 common shares at the public offering price less underwriting discounts. After deducting the underwriting discounts, the net proceeds of the public offering are expected to be approximately $28.2 million. The offering is expected to close on or about November 13, 2019, subject to customary closing conditions.

Affimed Announces Pricing of Public Offering of Common Shares

Heidelberg, Germany, November 7, 2019 - Affimed N.V. (Nasdaq: AFMD), a clinical stage biopharmaceutical company committed to giving patients back their innate ability to fight cancer, today announced that Genentech, a member of the Roche Group, has exercised its  final option for an exclusive target under the companies’ collaboration agreement to develop and commercialize novel NK cell engager-based immunotherapeutics generated from Affimed’s ROCK® platform to treat multiple cancers. The target selection triggers a milestone payment, in an undisclosed amount, to Affimed from Genentech.

Affimed Highlights Progress on NK Cell Engager Collaboration with Genentech

Heidelberg, Germany, November 7, 2019 - Affimed N.V. (Nasdaq: AFMD), a clinical stage biopharmaceutical company committed to giving patients back their innate ability to fight cancer, today announced that its Investigational New Drug application (IND) has cleared the required 30-day review by the U.S. Food and Drug Administration (FDA) and is in effect for a Phase 1/2a clinical trial of AFM24, a tetravalent, bispecific epidermal growth factor receptor (EGFR)- and CD16A-binding innate cell engager, in patients with advanced cancers known to express EGFR.

Affimed Announces FDA Clearance of IND to Commence First-in-Human Phase 1/2a Study of AFM24 for the Treatment of EGFR-Expressing Cancers

Affimed N.V. (AFMD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report.

Affimed N.V. (AFMD) May Report Negative Earnings: Know the Trend Ahead of Q3 Release

Shares have risen by over 50% since my initial recommendation and have lost over half their value since my latest update.

Affimed: Updates To Thesis, Meaningful Catalysts In 2020

IND application submitted for first-in-human study of AFM24, a bispecific EGFR/CD16A innate cell engager for solid tumors

Affimed Reports Progress on Key Clinical Development Programs

 Heidelberg, Germany, August 28, 2019 - Affimed N.V. (Nasdaq: AFMD), a clinical stage biopharmaceutical company committed to giving patients back their innate ability to fight cancer, today announced its participation in the following upcoming investor conferences in September:

Affimed to Participate in Investor Conferences in September

Affimed N.V. (AFMD) CEO Adi Hoess on Q2 2019 Results - Earnings Call Transcript

Arrowhead Pharmaceuticals

Incyte

Recro Pharma

Repligen

Veracyte

Vertex Pharmaceuticals

Despite the trade dispute with China, these biotech stocks each earn top marks in Portfolio Grader for fundamentals, earnings and momentum.

7 Top-Rated Biotech Stocks to Invest In Today

Affimed (AFMD) exceeds earnings and sales estimates in the first quarter of 2019. The company also plans to focus its research and development investments.

Affimed (AFMD) Earnings and Sales Exceed Estimates in Q1

Affimed N.V. (AFMD) CEO Adi Hoess on Q1 2019 Results - Earnings Call Transcript

Affirmed Therapeutics (AFMD) delivered earnings and revenue surprises of 118.75% and 90.42%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?

Affirmed Therapeutics (AFMD) Beats Q1 Earnings and Revenue Estimates

Affirmed Therapeutics (AFMD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Affirmed Therapeutics (AFMD) May Report Negative Earnings: Know the Trend Ahead of Q1 Release

Affimed (AFMD) is likely to provide update on the progress of its pipeline candidates when its reports first-quarter results.

What's in Store for Affimed (AFMD) This Earnings Season?

Affirmed Therapeutics (AFMD) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Affirmed Therapeutics (AFMD) Moves to Buy: Rationale Behind the Upgrade

Affirmed Therapeutics (AFMD) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

What Makes Affirmed Therapeutics (AFMD) a New Strong Buy Stock

Affimed N.V. (AFMD) CEO Adi Hoess on Q4 2018 Results - Earnings Call Transcript

News for Affimed Stock (AFMD)